WallStreetZenWallStreetZen

NASDAQ: ARDS
Aridis Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for ARDS

Based on 1 analyst offering 12 month price targets for Aridis Pharmaceuticals Inc.
Min Forecast
$10.00+2,400%
Avg Forecast
$10.00+2,400%
Max Forecast
$10.00+2,400%

Should I buy or sell ARDS stock?

Based on 2 analysts offering ratings for Aridis Pharmaceuticals Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 50%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ARDS stock forecasts and price targets.

ARDS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Top 18%
83
BuyMaintains$10.00+2,400.00%2023-01-26
Maxim Group
Bottom 2%
2
HoldDowngradesN/AN/A2022-08-16

1 of 1

Forecast return on equity

Is ARDS forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is ARDS forecast to generate an efficient return on assets?
Company
N/A
Industry
14.04%

ARDS earnings per share forecast

What is ARDS's earnings per share in the next 1 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.53

ARDS revenue forecast

What is ARDS's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$28.6M+898.25%
Avg 2 year Forecast
$67.8M+2,266.49%
Avg 3 year Forecast
$113.2M+3,851.13%
ARDS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ARDS revenue growth forecast

How is ARDS forecast to perform vs Biotechnology companies and vs the US market?
Company
394.49%
Industry
67.87%
Market
9.33%
ARDS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ARDS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ARDS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ARDS$0.40$10.00+2,400.00%Buy
ACGN$2.26$2.00-11.50%Hold
LABP$0.27$1.05+296.23%Hold
PTIX$1.95$4.00+105.13%Strong Buy
VYNE$2.59$1.50-42.08%Buy
View Top Biotech Stocks

Aridis Pharmaceuticals Stock Forecast FAQ

Is Aridis Pharmaceuticals Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ARDS) stock is to Buy ARDS stock.

Out of 2 analysts, 0 (0%) are recommending ARDS as a Strong Buy, 1 (50%) are recommending ARDS as a Buy, 1 (50%) are recommending ARDS as a Hold, 0 (0%) are recommending ARDS as a Sell, and 0 (0%) are recommending ARDS as a Strong Sell.

If you're new to stock investing, here's how to buy Aridis Pharmaceuticals stock.

What is ARDS's earnings growth forecast for 2023-2023?

(NASDAQ: ARDS) Aridis Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 17.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 26.86%.

Aridis Pharmaceuticals's earnings in 2023 is -$32,794,000.

In 2023, ARDS is forecast to generate -$11,026,544 in earnings, with the lowest earnings forecast at -$28,086,480 and the highest earnings forecast at $6,241,440.

What is ARDS's revenue growth forecast for 2023-2025?

(NASDAQ: ARDS) Aridis Pharmaceuticals's forecast annual revenue growth rate of 394.49% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 67.87%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.33%.

Aridis Pharmaceuticals's revenue in 2023 is $2,865,000.On average, 2 Wall Street analysts forecast ARDS's revenue for 2023 to be $595,017,280, with the lowest ARDS revenue forecast at $31,207,200, and the highest ARDS revenue forecast at $1,158,827,360. On average, 1 Wall Street analysts forecast ARDS's revenue for 2024 to be $1,410,565,440, with the lowest ARDS revenue forecast at $1,410,565,440, and the highest ARDS revenue forecast at $1,410,565,440.

In 2025, ARDS is forecast to generate $2,355,103,360 in revenue, with the lowest revenue forecast at $2,355,103,360 and the highest revenue forecast at $2,355,103,360.

What is ARDS's forecast return on assets (ROA) for 2023-2025?

(NASDAQ: ARDS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 14.04%.

What is ARDS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ARDS price target, the average ARDS price target is $10.00, with the highest ARDS stock price forecast at $10.00 and the lowest ARDS stock price forecast at $10.00.

The Wall Street analyst predicted that Aridis Pharmaceuticals's share price could reach $10.00 by Jan 26, 2024. The average Aridis Pharmaceuticals stock price prediction forecasts a potential upside of 2,400% from the current ARDS share price of $0.40.

What is ARDS's Earnings Per Share (EPS) forecast for 2023-2023?

(NASDAQ: ARDS) Aridis Pharmaceuticals's current Earnings Per Share (EPS) is -$1.81. In 2023, ARDS's EPS is forecast to hit -$0.53 (min: -$1.35, max: $0.30).

What is ARDS's forecast return on equity (ROE) for 2023-2025?

(NASDAQ: ARDS) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.